Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CCNH | P51946 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22747536 | 0.90 | MAPT (0.53) | MAPTRAPGEF4FFAR1CDK1CCNB1 | |
| SCHEMBL22747375 | 0.82 | MAPT (0.56) | MAPTRAPGEF4FFAR1CDK1CCNB1 | |
| SCHEMBL22829737 | 0.81 | RAPGEF4 (0.53) | RAPGEF4SYKKIF11FFAR1CDK1 | |
| SCHEMBL22747359 | 0.80 | MAPT (0.53) | MAPTRAPGEF4FFAR1CDK1CCNB1 | |
| SCHEMBL31331710 | 0.76 | MAPT (0.49) | MAPTCYP1A2CYP3A4CYP2C19LMNA | |
| SCHEMBL22718422 | 0.76 | MAPT (0.49) | MAPTCYP1A2CYP3A4CYP2C19LMNA | |
| SCHEMBL22718236 | 0.75 | AKR1C3 (0.58) | MAPTFFAR1CDK1CCNB1CCNA2 | |
| SCHEMBL29438887 | 0.75 | AKR1C3 (0.58) | MAPTFFAR1CDK1CCNB1CCNA2 | |
| SCHEMBL22719651 | 0.72 | RAPGEF4 (0.59) | MAPTRAPGEF4KIF11CYP1A2CYP3A4 | |
| SCHEMBL22719750 | 0.72 | MEN1 (0.60) | RAPGEF4CYP1A2CYP3A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | MAPT 507/4885RAPGEF4 687/4885SYK 3741/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | MAPT 507/4885RAPGEF4 687/4885SYK 3741/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | MAPT 507/4885RAPGEF4 687/4885SYK 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.